Jim Cramer Rejects UiPath Despite Cheap Valuation, Backs Affirm

LongbridgeAII'm LongbridgeAI, I can summarize articles.

On CNBC’s “Mad Money Lightning Round,” Jim Cramer said UiPath Inc. (NYSE:PATH) is a “cheap, cheap stock, but it has no catalyst, so I have to vote it off the island.”

UiPath said it will report third-quarter fiscal 2027 financial results after the closing bell on Thursday, Dec. 3.

Karman Holdings Inc. (NYSE:KRMN) is so “darn cheap. I can’t go against it here. I have to tell you, I think you got something right here,” Cramer said.

On Nov. 5, Karman reported better-than-expected third-quarter financial results and raised its FY26 sales guidance above estimates.

When asked about Affirm Holdings Inc. (NASDAQ:AFRM), he said, “We’re fighting the Fed if we buy the stock. If you want to start up a new position, I bless it right here.”

Affirm, on Nov. 5, reported first-quarter revenue of $1.262 billion, up 35% year-over-year. The revenue total beat a Street consensus estimate of $1.211 billion, according to data from Benzinga Pro. The company reported first-quarter earnings of 47 cents per share, beating a Street consensus estimate of 38 cents per share.

Cramer said Onto Innovation Inc. (NYSE:ONTO) is a good company, but it’s going to move lower because it’s “too expensive in an environment where the Fed is fighting inflation.”

On Nov. 16, Onto Innovation announced a $400 million share repurchase program.

When asked about NIO Inc. (NYSE:NIO), he said, “I got to tell you, $2 stocks, you know where they can go? They stop at zero, and that’s always been the saving grace of a $2 stock. I suggest that you, as long as you don’t mind losing the two bucks, you can hold on for it.”

Nio will report unaudited third-quarter financial results on Tuesday, Dec. 1.

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) is an “inexpensive” stock, Cramer said. “I happen to like his partner Regeneron (NASDAQ:REGN) more, though. Just for the record, Regeneron, Vertex (NASDAQ:VRTX), and Amgen (NASDAQ:AMGN) all work better.”

On Nov. 4, Alnylam Pharmaceuticals announced it authorized a $1 billion share repurchase program.

Price Action:

  • UiPath shares fell 4.3% to settle at $11.23 on Thursday.
  • Karman shares declined 3.5% to close at $32.99 during the session.
  • Affirm shares dipped 3.4% to settle at $56.91.
  • Onto Innovation shares fell 2.5% to close at $195.93.
  • Nio shares declined 4% to settle at $2.66 on Thursday.
  • Alnylam Pharmaceuticals shares slipped 1.1% to close at $147.82.

Photo: created using images / Shutterstock

Login to unlock1,520characters for free

Due to copyright restrictions, please log in to your Longbridge account to view this content.
Thank you for your understanding and support of licensed content.